Allergan: Botox pack shots and award reposts on Instagram found to promote a POM to the public

• An aesthetics clinic owner/medical director complained that Allergan Limited promoted Botox (botulinum toxin type A), a prescription only medicine (POM), on social media.
• The complaint focused on content on the JuvedermUK patient-facing Instagram account (Juvederm is a dermal filler registered as a medical device) that included Botox pack shots.
• Two Instagram Stories reposted on the JuvedermUK account contained Botox packaging: one still image with a Botox pack shot in the foreground, and one video where a Botox vial/carton appeared in the background for the final 4 seconds of a 14-second video.
• The complainant also cited Instagram live-streaming posts/videos from the Aesthetics Awards 2019 uploaded to a senior employee’s personal Instagram page referring to Botox as “Injectable Product of the Year 2019”, and similar material posted by other team members.
• Allergan said it had no intention to promote Botox to the public, stated the posts were brief/limited reach, and said it identified and removed the employee posts within 24 hours and reminded staff about requirements for social media and POMs.
• Allergan acknowledged its third-party reposting process should have prevented reposting content containing Botox pack images and proposed corrective actions including making the reposting process a formal SOP, improving training record capture, and adding a second-person check before reposts went live.

• The Panel ruled that the two JuvedermUK Instagram Stories containing Botox pack shots amounted to promotion of a POM to the public on a platform used by members of the public.
• The Panel ruled that the senior manager’s personal Instagram repost about Botox being “Injectable Product of the Year” (and its repost by a salesforce colleague) also promoted a POM to the public on the balance of probabilities.
• The Panel found Allergan’s social media policy documents were not sufficiently robust/explicit regarding POM restrictions, including that the corporate reposting policy was not a formal SOP with accurate training records and that the personal social media SOP made no reference to POMs.
• The Panel ruled breaches of Clauses 26.1, 9.1 and 2 (including that high standards had not been maintained and that Allergan had brought discredit upon and reduced confidence in the pharmaceutical industry).

• Clause 26.1 (promotion of prescription only medicines to the public) – breached.
• Clause 9.1 (high standards) – breached.
• Clause 2 (bringing discredit to, and reducing confidence in, the pharmaceutical industry) – breached.

• No explicit additional sanctions stated beyond the required undertaking/corrective actions described in the report

Why this matters: This case shows how easily a POM can be “promoted” to the public via social media even without explicit claims—pack shots, award statements, and reposted third-party content can be enough, particularly on mixed-audience channels.

Where teams typically slip up (interpretation):

• Assuming “it’s mainly about a device” (eg, Juvederm) makes incidental POM visibility acceptable.
• Treating Stories/short-lived content as lower risk because it is brief, disappears in 24 hours, or has limited views.
• Relying on individual judgment for reposting without a documented SOP, auditable training records, and a second-line check.

The control that would have prevented it: A formal, documented SOP for corporate reposting plus mandatory dual review (including explicit checks for any POM identifiers such as pack shots/vials, brand names, award claims) and a personal social media policy that explicitly addresses POM restrictions.

What I’d check in the job bag:

• The approved SOP/work instruction for reposting/curation on corporate social accounts, including explicit “no POM reference” definitions (images/pack shots, audio, hashtags, etc).
• Evidence of training assignment and completion (LMS records) for everyone with posting/reposting permissions, including onboarding records.
• Documented second-person review logs for each repost (who checked, when, what was checked).
• Personal social media policy content and training materials showing clear POM restrictions for employees posting in a professional/personal capacity.
• Removal/correction records and internal communications reminding staff of POM social media requirements following the incident.

What the sanctions tell you (interpretation):

• The ruling emphasizes system controls (SOPs, training records, and review structure) rather than intent; “no intention” did not mitigate the breach finding.
• Clause 2 indicates the Panel viewed repeated policy failures (including by a senior manager) as reputationally serious.
• Expect heightened scrutiny where companies operate both devices and POMs in the same therapy area and use consumer-facing social channels.

3 questions to ask your team this week:

1. Do we have any consumer-facing or mixed-audience channels where a POM could appear incidentally (background pack, clinic shelf, award graphic), and how do we prevent that?
2. Is reposting/resharing governed by a formal SOP with dual review and auditable training records for every authorized poster?
3. Do our employee personal social media rules explicitly cover POM restrictions, and do we monitor and reinforce them—especially around events/awards?